ProShare Advisors
PHAT icon

ProShare Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

ProShare Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,246
Closed -$114K – 1992
2026
Q1 		$114K Sell
10,246
-131
-1% -$1.66K ﹤0.01% 1685
2025
Q4 		$172K Buy
+10,377
New +$148K ﹤0.01% 1766
2025
Q3 		– Sell
-11,265
Closed -$108K – 2087
2025
Q2 		$108K Sell
11,265
-449
-4% -$2.48K ﹤0.01% 1866
2025
Q1 		$73.4K Sell
11,714
-2,575
-18% -$15.6K ﹤0.01% 1892
2024
Q4 		$116K Buy
14,289
+3,804
+36% +$47.1K ﹤0.01% 2043
2024
Q3 		$190K Buy
+10,485
New +$147K ﹤0.01% 1742

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ProShare Advisors's PHAT Position: Q2 2026 in Review

ProShare Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 10,246 shares — an estimated $114K sold.

ProShare Advisors first reported a position in PHAT in Q3 2024 and held it in 6 quarters. The position peaked at $190K in Q3 2024. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • ProShare Advisors reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • ProShare Advisors sold 10,246 Phathom Pharmaceuticals shares in Q2 2026, an estimated $114K.
  • ProShare Advisors first reported a position in Phathom Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • ProShare Advisors's Phathom Pharmaceuticals position peaked at $190K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.